No Data
No Data
YieldMax META Option Income Strategy ETF Declares $0.375 Dividend
'UnitedHealthcare CEO Fatally Shot In Midtown: Sources' - PIX11
Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
Marvell Technology Surges as Wall Street Praises Its 'All in' AI Mantra
Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.
Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.
Top 3 Tech And Telecom Stocks That May Implode This Quarter
151453268 witso : Hey Jess, lipsticks popping, nice roundup usual conundrums in play just have to hold tight.